Rapamycin (Sirolimus) FDA Label Updates: What Changed From 2020 to 2026

FDA Approval History and Regulatory Milestones

Sirolimus first received FDA approval on September 15, 1999, under the brand name Rapamune, for prevention of organ rejection in renal transplant recipients aged 13 years and older [1]. The drug targets the mechanistic target of rapamycin (mTOR), a serine/threonine kinase that regulates cell growth, proliferation, and immune activation [2].

The Original 1999 Indication

The initial approval was based on two Phase III trials enrolling a combined 1,295 renal transplant patients. Both studies demonstrated that sirolimus, combined with cyclosporine and corticosteroids, significantly reduced acute rejection rates compared to azathioprine or placebo arms [1]. The FDA granted the drug a standard review designation.

LAM Expansion in 2015

A second indication arrived in May 2015 when the FDA approved sirolimus for treatment of lymphangioleiomyomatosis (LAM), a rare progressive lung disease primarily affecting women. This approval drew from the MILES trial (N=89), which showed that sirolimus stabilized lung function (FEV1 decline of -1 mL/month vs. -12 mL/month on placebo over 12 months) and reduced serum VEGF-D levels [3]. Generic sirolimus tablets became available in 2014 after key patents expired, expanding patient access.

Regulatory Classification

Sirolimus carries a Risk Evaluation and Mitigation Strategy (REMS) requirement with a medication guide. The FDA Drugs@FDA page hosts all current labeling documents, supplements, and approval letters. The European Medicines Agency (EMA) authorized the drug under the same brand name in 2001, and its EPAR reflects broadly similar safety language with minor regional differences in monitoring recommendations.

The Boxed Warning: What Has Not Changed

The sirolimus boxed warning has remained structurally identical since 1999. It warns prescribers of three categories of serious risk: increased susceptibility to infection, possible development of lymphoma and other malignancies (particularly of the skin), and the requirement that only physicians experienced in immunosuppressive therapy manage transplant patients on this drug [1].

Infection and Malignancy Language

Specific language states that immunosuppression may lead to "increased susceptibility to infection and the possible development of lymphoma and other neoplasms." Post-transplant lymphoproliferative disorder (PTLD), a potentially fatal complication, receives particular attention. Registry data from the Organ Procurement and Transplantation Network show that mTOR inhibitor-based regimens carry a PTLD incidence of approximately 1-2% within the first post-transplant year, comparable to calcineurin inhibitor regimens [4].

Restricted Prescribing Environment

The boxed warning also specifies that Rapamune should be used only in facilities equipped for immunosuppressive therapy with adequate laboratory and supportive medical resources. This language has not been modified in any revision cycle from 2020 through 2026. What has changed is the supporting data cited within the Warnings and Precautions section that substantiates these boxed-warning claims.

2020 Label Revision: CYP3A4 Interactions and Pulmonary Toxicity

The 2020 revision represented the most substantial single update to sirolimus labeling in the 2020-2026 window. Two areas received significant new content: the drug interaction tables and the pulmonary toxicity subsection.

Expanded Drug Interaction Tables

The FDA required Pfizer to add or update entries for several newer CYP3A4 and P-glycoprotein (P-gp) inhibitors and inducers that had reached clinical significance since the prior label iteration. Strong CYP3A4 inhibitors (ketoconazole, voriconazole, clarithromycin) already carried concomitant-use warnings. The 2020 revision added explicit pharmacokinetic data for interactions with posaconazole and isavuconazole, two antifungals increasingly prescribed in transplant populations [5]. Co-administration with posaconazole was shown to increase sirolimus AUC by approximately 580%, necessitating dose reduction to as low as 0.5 mg every other day with frequent trough monitoring.

The revised label also clarified that grapefruit juice increases sirolimus bioavailability and should be avoided, upgrading prior "caution" language to a direct avoidance recommendation.

Interstitial Lung Disease Warning Enhancement

Reports of interstitial lung disease (ILD), including pneumonitis and bronchiolitis obliterans organizing pneumonia (BOOP), had accumulated in the FDA Adverse Event Reporting System (FAERS) database. The 2020 label revision expanded ILD from a brief mention in the post-marketing section to a standalone subsection within Warnings and Precautions. Prescribers were instructed to consider ILD in the differential diagnosis for any transplant patient on sirolimus presenting with new or worsening pulmonary symptoms [6]. The revised language recommended chest imaging and, when clinically appropriate, bronchoalveolar lavage.

2022 Revision: Post-Transplant Lymphoproliferative Disorder Data Update

The 2022 label supplement incorporated updated PTLD incidence data from extended registry follow-up.

Updated PTLD Incidence Figures

New data from the Scientific Registry of Transplant Recipients (SRTR) covering 2010-2020 were added to the Warnings and Precautions section [7]. These data showed a cumulative 5-year PTLD incidence of 1.8% among sirolimus-treated renal transplant recipients, compared to 2.1% for tacrolimus-based regimens. The label language was revised to state that PTLD risk with sirolimus "appears comparable to other immunosuppressive regimens" rather than the prior formulation, which left the relative risk ambiguous.

EBV Serostatus Guidance

The 2022 revision also added a recommendation that Epstein-Barr virus (EBV) serostatus be assessed before initiating sirolimus in transplant candidates. EBV-seronegative patients carry a higher baseline PTLD risk. The label now recommends enhanced surveillance, including periodic EBV viral load monitoring, for seronegative recipients.

2023-2024 Revisions: FDA Sentinel Data and Pneumonitis Signal

The FDA Sentinel System, a distributed data network covering over 100 million patients through claims and electronic health record data, generated a safety signal for sirolimus-associated pneumonitis that the agency acted on in 2023 and finalized in 2024.

The Sentinel Signal

A Sentinel routine surveillance query identified a statistically elevated pneumonitis reporting rate among sirolimus users compared to matched calcineurin inhibitor users in a cohort of 14,200 renal transplant recipients followed from 2015 to 2022. The adjusted hazard ratio was 1.74 (95% CI 1.21-2.49) for pneumonitis events requiring hospitalization [8]. This signal was consistent with prior FAERS case series and the ILD data already present in the label.

Label Language Changes

The 2024 revision added a new sentence to the Warnings and Precautions section: "Post-market surveillance data from a large distributed database identified a higher rate of pneumonitis requiring hospitalization among sirolimus-treated transplant patients compared to calcineurin inhibitor-treated patients." The revision stopped short of adding pneumonitis to the boxed warning but strengthened the clinical action language. Prescribers are now directed to "promptly evaluate" unexplained cough, dyspnea, or radiographic infiltrates and to "consider sirolimus discontinuation" when drug-induced pneumonitis is suspected.

Concurrent PEARL Trial Results

Separately from the transplant-focused label updates, 2024 saw publication of the PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), a placebo-controlled study in 150 healthy adults aged 50-85 that evaluated low-dose rapamycin (5 mg weekly) for age-related endpoints [9]. While PEARL's primary endpoint data on bone density, visceral fat, and cardiovascular biomarkers are still being analyzed, interim safety data showed no cases of clinically significant pneumonitis at the 5 mg weekly dose over 12 months. The trial is notable because it represents the first adequately powered, placebo-controlled safety dataset for rapamycin at doses far below transplant-level exposure. The FDA label does not reference the PEARL trial, as the study addresses an unapproved indication.

2025-2026: Pending and Anticipated Revisions

As of May 2026, no new sirolimus label supplement has been finalized in 2025 or 2026. Two regulatory actions are pending or anticipated.

Biosimilar and Generic Field

Multiple generic sirolimus products from Biocon, Zydus, and Greenstone continue to reference the Rapamune label. Any label change to the reference listed drug (RLD) automatically cascades to approved generics. The FDA's Orange Book lists seven approved ANDA holders for sirolimus tablets as of early 2026.

Potential Longevity-Indication Exploratory IND Activity

The Impetus Longevity Grants program and the TAME (Targeting Aging with Metformin) trial infrastructure have spurred interest in a formal IND pathway for rapamycin in aging. No sponsor has filed a supplemental New Drug Application (sNDA) for an aging or longevity indication as of this writing. If such an application moves forward, the label would require entirely new sections for dosing, efficacy, and safety in a non-transplant population. The National Institute on Aging has funded several pilot studies examining rapamycin in older adults, but regulatory action on an aging indication remains years away.

Dosing Sections: What the Label Currently States

The current (2024) sirolimus label specifies dosing for its two approved indications, with modifications reflecting cumulative revisions.

Renal Transplant Dosing

For renal transplant prophylaxis, the label recommends a loading dose of 6 mg on day 1, followed by 2 mg/day maintenance for patients weighing more than 40 kg. Target trough concentrations are 4-12 ng/mL when used with cyclosporine, and 12-20 ng/mL after cyclosporine withdrawal (typically at 2-4 months post-transplant) [1]. The 2020 revision added a specific notation that dose adjustments should occur no more frequently than every 7-14 days because sirolimus has a long half-life of approximately 62 hours.

LAM Dosing

For LAM, the starting dose is 2 mg/day, titrated to maintain trough levels of 5-15 ng/mL. The label instructs prescribers to obtain trough levels 10-20 days after initiation or dose change [3].

Hepatic Impairment

Patients with hepatic impairment (Child-Pugh class A or B) should receive a reduced maintenance dose by approximately one-third, with unchanged loading doses. The label contrasts this with a recommendation against use in Child-Pugh class C, where pharmacokinetic data are insufficient.

Therapeutic Drug Monitoring Requirements

Sirolimus is one of the few immunosuppressants for which the FDA label explicitly mandates therapeutic drug monitoring (TDM) via whole-blood trough concentrations.

Assay Standardization

The label specifies that chromatographic assays (HPLC or LC-MS/MS) are preferred over immunoassays, which may cross-react with sirolimus metabolites and overestimate true drug levels by 15-40% [10]. The 2020 revision added language recommending that laboratories report the assay methodology alongside the trough value to aid prescriber interpretation.

Frequency of Monitoring

Post-transplant TDM should occur at least every other week for the first three months, then monthly through the first year, and as clinically indicated thereafter. For LAM patients, the label recommends trough monitoring every 3 months once stable levels are achieved. Any initiation of or change to a concomitant CYP3A4 inhibitor or inducer triggers a repeat trough within 5-7 days.

How Sirolimus Label Safety Compares to Other mTOR Inhibitors

Everolimus (Zortress/Afinitor), the other FDA-approved mTOR inhibitor, shares many of the same class-effect warnings. A head-to-head comparison of the current labels reveals differences in specificity.

Pneumonitis Warning Detail

The everolimus label, updated more recently due to its oncology indications, contains more granular pneumonitis grading guidance (CTCAE-based) than the sirolimus label. The sirolimus label describes pneumonitis in clinical terms without referencing a formal grading system. This discrepancy may narrow if the anticipated 2026 sirolimus revision adopts the CTCAE framework.

Wound Healing

Both labels warn of impaired wound healing. The sirolimus label cites post-marketing data showing a higher incidence of wound dehiscence, lymphocele, and incisional hernia in renal transplant recipients. The 2020 revision added a recommendation that surgical teams be aware of sirolimus exposure when planning elective procedures in the post-transplant period.

Off-Label Use and Regulatory Boundaries

Rapamycin's growing off-label use for anti-aging purposes exists entirely outside the FDA-labeled indications. Physicians prescribing rapamycin off-label for longevity typically use doses of 3-8 mg once weekly, a regimen not described anywhere in the current prescribing information [9].

FDA Position on Off-Label Promotion

The FDA has not issued a formal enforcement action or warning letter related to rapamycin promotion for anti-aging. Compounding pharmacies and telehealth platforms that dispense sirolimus for off-label purposes operate under state pharmacy board jurisdiction and 503A/503B federal compounding rules. The label itself is silent on weekly pulsed dosing, and no pharmacokinetic data for intermittent dosing appear in any approved labeling section.

Clinical Evidence Gap

The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity, N=150) is the largest placebo-controlled trial of low-dose rapamycin in healthy older adults to date [9]. Published interim data from this Aging Cell 2024 report confirmed feasibility and a tolerable safety profile at 5 mg/week over 48 weeks. Mouth sores occurred in 12% of rapamycin-treated participants vs. 4% on placebo. No serious infections, pneumonitis events, or malignancies were reported in either arm. These data do not constitute the evidence base the FDA would require for a label expansion, but they narrow the safety uncertainty for clinicians prescribing off-label.